George N. Ioannou

University of Washington
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (15)

Supplementary Table S4. Competing risks proportional hazards regression for the associations between race/ethnicity and risk of HCC, decompensated cirrhosis, and death in patients with cirrhosis overall and by cirrhosis etiology

Year:

2025

Supplementary Table S2. ICD-9 codes for type 2 diabetes mellitus, alcohol use disorders, hemochromatosis, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, human immunodeficiency virus, and low socioeconomic status

Year:

2025

Supplementary Table S5. Association between race/ethnicity and risk of cirrhosis decompensation in patients with cirrhosis overall and by cirrhosis etiology: follow-up from cirrhosis diagnosis (2001-2014) to 2020

Year:

2025

Supplementary Table S6. Association between race/ethnicity and risk of all-cause mortality in patients with cirrhosis overall and by cirrhosis etiology: follow-up from cirrhosis diagnosis (2001-2014) to 2020

Year:

2025

Background: Among patients with cirrhosis, it remains unclear whether there are racial/ethnic differences in cirrhosis complications and mortality. We examined the associations between race/ethnicity and risk for hepatocellular carcinoma (HCC), cirrhosis decompensation, and all-cause mortality overall and by cirrhosis etiology. Methods: US Veterans diagnosed with cirrhosis from 2001 to 2014 ( n = 120,992), due to hepatitis C virus (HCV; n = 55,814), alcohol-associated liver disease (ALD; n = 36,323), hepatitis B virus (HBV; n = 1,972), nonalcoholic fatty liver disease (NAFLD; n = 17,789), or other ( n = 9,094), were followed through 2020 for incident HCC ( n = 10,242), cirrhosis decompensation ( n = 27,887), and mortality ( n = 81,441). Multivariable Cox proportional hazards regression was used to estimate adjusted hazard ratios (aHR) and 95% confidence intervals (CI). Results: Compared with non-Hispanic White patients, Hispanic patients had higher risk for HCC overall (aHR, 1.32; 95% CI, 1.24–1.41) and by cirrhosis etiology, particularly for ALD- (aHR, 1.63; 95% CI, 1.42–1.87) and NAFLD-cirrhosis (aHR, 1.76; 95% CI, 1.41–2.20), whereas non-Hispanic Black patients had lower HCC risk in ALD- (aHR, 0.79; 95% CI, 0.63–0.98) and NAFLD-cirrhosis (aHR, 0.54; 95% CI, 0.33–0.89). Asian patients had higher HCC risk (aHR, 1.70; 95% CI, 1.29–2.23), driven by HCV- and HBV-cirrhosis. Non-Hispanic Black patients had lower risk for cirrhosis decompensation overall (aHR, 0.71; 95% CI, 0.68–0.74) and by cirrhosis etiology. There was lower risk for mortality among all other racial/ethnic groups compared with non-Hispanic White patients. Conclusions: Race/ethnicity is an important predictor for risk of developing HCC, decompensation, and mortality. Impact: Future research should examine factors underlying these racial/ethnic differences to inform prevention, screening, and treatment for patients with cirrhosis.

Year:

2025

Supplementary Table S6. Association between race/ethnicity and risk of all-cause mortality in patients with cirrhosis overall and by cirrhosis etiology: follow-up from cirrhosis diagnosis (2001-2014) to 2020

Year:

2024

Supplementary Table S5. Association between race/ethnicity and risk of cirrhosis decompensation in patients with cirrhosis overall and by cirrhosis etiology: follow-up from cirrhosis diagnosis (2001-2014) to 2020

Year:

2024

Supplementary Table S4. Competing risks proportional hazards regression for the associations between race/ethnicity and risk of HCC, decompensated cirrhosis, and death in patients with cirrhosis overall and by cirrhosis etiology

Year:

2024

Supplementary Table S5. Association between race/ethnicity and risk of cirrhosis decompensation in patients with cirrhosis overall and by cirrhosis etiology: follow-up from cirrhosis diagnosis (2001-2014) to 2020

Year:

2024

Supplementary Table S2. ICD-9 codes for type 2 diabetes mellitus, alcohol use disorders, hemochromatosis, primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, human immunodeficiency virus, and low socioeconomic status

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2020

Collaborators (4)

Trang VoPham

Associate Professor

University of Washington

UNITED STATES
View details

Ziding Feng

Professor

Fred Hutch Cancer Center

UNITED STATES
View details

Nicole Kim

Assistant Professor

University of Washington

UNITED STATES
View details

Jason A. Mendoza

Professor

University of Washington

UNITED STATES
View details